Bavarian Nordic has successfully built its patent portfolio on and around its core technology; MVA-BN®. The patent portfolio has been developed to ensure that Bavarian Nordic can optimise the commercial value of the discoveries in the company’s research and development activities. In addition the portfolio will ensure protection against competitors’ use of similar products and technologies within Bavarian Nordic’s core business areas.
Bavarian Nordic’s patent portfolio consists of 30 patent families. Each patent family consists of numerous corresponding issued/ granted foreign patents, pending applications, continuations and divisional applications. The patent portfolio consists of over 350 pending patent applications and more than 400 granted/issued patents.
A strong patent portfolio underpins Bavarian Nordic’s competitive position in MVA-based vaccines.
Bavarian Nordic’s competitive IP protection gives exclusive rights to manufacture, sell and market its MVA-based technology globally. Bavarian Nordic’s exclusive rights cover certain aspects of recombinant MVA vaccines for cancer, HIV and other infectious indications created by inserting foreign genes into the MVA genome. In addition, Bavarian Nordic has acquired exclusive rights to non-MVA technologies including other viruses and production processes from other patent holders.
|
